Member Info for hants

I'm looking at closing some of my NCYT position tomorrow and adding SNG. Whilst there's a lot of hype over thereat NCYT, the demand for that test could dramatically reduced if AVCT (my largest holding) release positive RNS / are successful - so I'm a little nervous on that one and feel that money could be better invested here.

I feel SNG is a well run company, has a lot of promise and is already well advanced. It's also very local to me, which is a nice touch I guess!

kewjosh - Can't find my source, but I've written a note on my pad in front of me that its an 8 week trial.

Southampton is the first trial location, but there's several.

Hopefully somebody else can confirm what I've just said?

Interesting article. Certainly a lot of competition here. However, whilst that's a saliva tet it still needs a lab...
The Avacta USP is still there as far as I know...

Would anybody be kind enough to bring me up to speed on Genedrive please? I've read the 25th of March RNS which says a test should be available in 8 weeks.

I've also seen the CEO interview on proactive, 31st March.

Seems like radio silence for the last two weeks? Have I missed anything?

Not to my knowledge, Vegas. I can't give a concrete answer, however note the below:

1. In that video he talks about their Zika virus test and that it was very specific.

2. Also, extract from Cambridge Indepdendent:
“We have demonstrated before in the case of the Zika virus that the Affimer platform can very quickly provide highly-specific reagents in response to an outbreak of an infectious disease."

Also, my thought would be that whilst an hour is great, ten minutes is a whole different league. Lets say you're an airline needing to test passengers before they board an aircraft, or a company testing employees when they arrive at work etc. An hour would be workable... but still be less than ideal...

Hi Vegas,

I would start by watching this video if you haven't already:
https://avacta.com/avacta-ceo-alastair-smith-provides-update-on-covid-19-collaboration-with-cytiva/
The wording used in this video inspires confidence IMO. It all sounds very definite, not at all flakely.

1. Avacta are now partnered with Cytiva, who are part of GE - so this is very positive indeed. Can't see they would be working with Avacta if their offering was less than very promosing. There's lots of phamas racing to make Covid products, there must be a reason they're on board here surely?

2. It appears the product should be very acccurate (see video for explanation).

3. They have cancer products in the pipeline. In the (what seems unlkely) event of no success in this product, there's more to come anyway! Search for Myles McNulty on twitter and read his pinned post. I would suggest making a cup of tea first, the document the post links to is about 20 pages.

I'm really surprised this AVCT board isn't busier than it is.

There's strong indications that Avacta will have a working test and it won't be long. Huge partnership with Cytiva. Plus, it was a good investment regardless of Covid-19 beause of cancer treatments in the pipeline.

I imagine it won't be long before everybody piles in here. I still have money in NCYT, as I'm sure a lot of others do. I think there will be profit taking once the hysteria calms down over there, and then people will start looking for the next one.

Pleased to be in early on this, I feel very confident about it.

https://www.proactiveinvestors.co.uk/LON:SNG/Synairgen-PLC/

Perhaps even faster than toilet roll?

I agree. AVCT is now my biggest holding. I intend to sell NCYT for a nice profit shortly and I will likely increase my holding in AVCT further.

Possibly Genedrive too, but I feel the market for testing is going to be much larger than the market for treatment. Of course, as testing increasing, the spread and need for treatment should decrease (or that's what one would hope?). Therefore, investing in Genedrive almost feels like a bet against myself. That said, there are other positive aspects to that company too, such as with AVCT.

That was supposed to say Thursday*

Mixed up on the days at the moment!

Yes I think that's where it needs to go. Novacyt have been quick off the mark hence their success, but I don't think their product is the end game here. That said, the market for testing is going to be so big we will probably see success from a lot of companies simultaneously.

I've held NCYT since the beggining of last week. Tried to sell on the spike Friday but to no avail so still holding. I think NCYT still has some way to go so in some way I'm happy it didn't go through. I believe there's money to be made here still, BUT within a couple of months the landscape of testing products may have moved on.

Instant tests for consumer use are what is needed.

JDC2020 - that test is CE rated for professionals.

Upup - AVCT should have the saliva test somewhere around the end of May, according to RNS. Aimed at consumers. If that happens, it will be a game changer and make a lot of these other tests obsolete fairly quickly IMO.

And sorry - yes - what B2HS2L said. This is an anti-gen test which tells you whether you have Covid 19, not an antibody test which tells you whether you've had Covid 19.

If successful, this would allow the world to start returning to normality again.

It's also worth considering - antigen is a test which people could be using a lot, possibly as much as daily if you're going into an office, boarding a plane etc. My guess would be that there will be a company who's test is accepted to be the best. However, there may be some others which are not far behind and also plenty accurate enough. The market for this could be so huge there's space for several companies. One company might not be able to produce them fast enough anyway.

Disclaimer: This is purely my own speculation, but seems reasoned IMO.

DYOR etc.

Sorry, that's supposed to be NCYT. I type that wrong every time.

The Surescreen test is CE marked for professional use only. I can't recall my source on this, but my understanding is the Avacta test would be available to consumers.

I can't give technical answer to what Avactas advantage may be, if any. It's beyond my level of understanding and probably the same for most others on this board. However, their partnership with an enormous company like Cytiva suggests there's something in this.

Why would Cytiva choose Avacta over all the others if it was anything less than extremely promising?

I'm significantly invested because I think the risk is largely mitigated by Avacta's cancer treatment project. If they don't succeed on Covid-19, there's a second (and possibly even bigger) opportunity with their cancer treatment prospects - assuming you're happy to have your money tied up mid to long term.

I'm also in NYCT, but I intend to close out fairly soon on that. My feeling there is the opposite to Avacta. Within a few weeks, there could be a consumer CE approved test which would significantly reduce NYCT's market, possibly even making it obsolete.

So in summary - Avacta has the backing of one of an enormous pharma company. And if they fail, there's more in the pipeline so all is not lost.

I think there's a long way to go on this one. I'm not brave enough to hazard a guess at how far, though.A lot has been going on this week and I'm excited to see what happens after the easter break.

I'm invested in Novacyt and Avacta. Novacyts success is their speed in bringing a product to market. The potential with Avacta is that their product (if successful) can be used by consumers in their everyday lives as it just needs a saliva sample.

Avacta are a few weeks off at least, but as are Genedrive as far as I can tell. Genedrive (and Novacyt) might find their products are obsolete if Avacta are successful. Obviously Novacyt are signifcantly ahead and already have a product out there, but I'm struggling to see the upside in Genedrive.

I've only done 20 mins of research and reading, but just looking for other's thoughts. I'm wondering if it's worth having a punt here, but not convinced at the moment. The competition seems to be better or further advanced.

Any nuggets of information that I might be missing here?

My understanding of the ceph test is that its for use by medical staff? The machines will be in hospitals. It isn't for use by consumers as far as I'm aware.

Somebody please correct me if I've got that wrong.